Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05840055 · ClinicalTrials.gov registry record · NA
ACT with NMOSD Patients and Caregivers Pilot Study
A NA study, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- NA
- Development phase
- 43
- Enrollment target
NCT05840055: Completed NA study, sponsored by Thomas Jefferson University.
NCT05840055 is a NA study that has completed, run by Thomas Jefferson University. The registered enrollment target is 43 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05840055, a NA study, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
Study Summary
This study will examine the effectiveness of a neuromyelitis optics spectrum disorder (NMOSD) specific Acceptance and Commitment Therapy (ACT) intervention at reducing anxiety and depression in individuals with NMOSD and their caregivers/loved ones and improving overall health outcomes in individuals with NMOSD.
Primary Outcome
The Generalized Anxiety Disorder Questionnaire-7 is a seven item self-report questionnaire of anxiety symptom severity, with possible scores ranging from 0-21. Higher scores indicate higher anxiety symptom severity.
Interventions
- BEHAVIORAL Acceptance and Commitment Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2024-11-21 |
| Phase | NA |
What the finished NCT05840055 record still lists
NCT05840055 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Acceptance and Commitment Therapy is the first listed.
NCT05840055 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05840055 about?
NCT05840055 is a clinical study titled "ACT with NMOSD Patients and Caregivers Pilot Study". This study will examine the effectiveness of a neuromyelitis optics spectrum disorder (NMOSD) specific Acceptance and Commitment Therapy (ACT) intervention at reducing anxiety and depression in individuals with NMOSD and their caregivers/loved ones and improving overall health outcomes in individual...
What is the current status of trial NCT05840055?
This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2023-08-01. Estimated completion is 2024-11-21.
What interventions are being tested in trial NCT05840055?
The interventions under investigation include: Acceptance and Commitment Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT05840055?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05840055's enrollment target sits among peer trials
43 1435th of 2000 higher than 565 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI